Back to Results

Phibro Animal Health Corporation (PAHC)

Featured in Small-Cap Stocks

Phibro Animal Health Corporation is a U.S.-listed common stock on NASDAQ under the symbol PAHC. The company operates in animal health and mineral nutrition, with activities spanning North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its business is organized into three segments: Animal Health, Mineral Nutrition, and Performance Products.

Phibro develops, manufactures, and markets products used in food and companion animal applications, including poultry, swine, cattle, aquaculture, and dogs. Its portfolio includes antibacterials, anticoccidials, nutritional specialty products, and vaccines and vaccine adjuvants. The company also works on microbial and bioproduct solutions for animal health and nutrition, along with certain environmental, industrial, and agricultural uses. In addition, it supplies trace mineral formulations for livestock feed and specialty ingredients used in personal care, industrial chemicals, and catalyst applications. Founded in 1946 and based in Teaneck, New Jersey, the company also serves customers through local sales offices, wholesalers, feed manufacturers, and distributors.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-PAHC
$37.22
12.5% Upside
Fair
$45.60
37.9% Upside
Undervalued
Great
—
—
0.48
1.5%
September 2, 2026
14.1x
3.7x
0.9x
1.341 B
2.058 B
37.0%
51.5%
3.2
20.4%
13.4%
Valuation • Fair Value

Phibro Animal Health Corporation (NASDAQ-PAHC) Fair Value by Valuation Model

Compare the primary fair value estimate for Phibro Animal Health Corporation (NASDAQ-PAHC) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$37.22

Estimated upside of 12.5% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$42.47

Discounted cash flow valuation reference.

Ben Graham Formula Value

$26.05

Classic Ben Graham valuation formula reference.

DDM Fair Value

$51.72

Dividend discount model valuation reference.

EPV Fair Value

$19.38

Earnings power value estimate.

Comps Fair Value

$32.52

Comparable-company valuation reference.

Analyst Price Target

$45.60

Analysts imply upside of 37.9%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Phibro Animal Health Corporation (NASDAQ-PAHC) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Phibro Animal Health Corporation (NASDAQ-PAHC)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.5 B

Current operating scale indicator.

Revenue Forecast

1.5 B

Forward revenue estimate.

EBITDA

234.8 M

Current operating profitability reference.

EBITDA Forecast

253 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Phibro Animal Health Corporation (NASDAQ-PAHC) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Phibro Animal Health Corporation (NASDAQ-PAHC)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.32

No elevated caution signal from this screen.

Altman Z-Score

3.2

Relatively strong balance-sheet zone.

FCF / Net Income

13.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Phibro Animal Health Corporation (NASDAQ-PAHC). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Phibro Animal Health Corporation (NASDAQ-PAHC)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 2, 2026

Days to Earnings

43

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

1.5%

Income yield reference.

Upcoming Dividend

0.48

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

20.4%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Phibro Animal Health Corporation (NASDAQ-PAHC), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Phibro Animal Health Corporation (NASDAQ-PAHC) Stock Forecast & Technical Outlook

Review Phibro Animal Health Corporation (NASDAQ-PAHC) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Phibro Animal Health Corporation (NASDAQ-PAHC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Phibro Animal Health Corporation (NASDAQ-PAHC) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Phibro Animal Health Corporation (NASDAQ-PAHC) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Phibro Animal Health Corporation (NASDAQ-PAHC) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Phibro Animal Health Corporation (NASDAQ-PAHC) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Phibro Animal Health Corporation (NASDAQ-PAHC)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Phibro Animal Health Corporation (NASDAQ-PAHC) has a Hold consensus, with 0 buy, 3 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 3
Sell 0
FAQ • Fast Investor Answers

Phibro Animal Health Corporation (NASDAQ-PAHC) Stock FAQ

Quick answers about Phibro Animal Health Corporation (NASDAQ-PAHC) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$37.22
Estimated upside 12.5%
Valuation Rating
Undervalued
Estimated upside of 12.5%
Analyst Target
$45.60
Implied upside 37.9%
Financial Health
Great
Current financial-health read

The current fair value estimate for Phibro Animal Health Corporation (NASDAQ-PAHC) is $37.22. This implies an estimated upside of 12.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 12.5% versus the current market price.

The available analyst price target for Phibro Animal Health Corporation (NASDAQ-PAHC) is $45.60. The analyst target implies estimated upside of 37.9%.

The current financial health read for Phibro Animal Health Corporation (NASDAQ-PAHC) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Phibro Animal Health Corporation (NASDAQ-PAHC) is September 2, 2026.

Based on the current data, dividend yield is 1.5%, upcoming dividend amount is 0.48.

The current P/E ratio listed for Phibro Animal Health Corporation (NASDAQ-PAHC) is 14.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Phibro Animal Health Corporation is 1.341 B.

The current enterprise value listed for Phibro Animal Health Corporation is 2.058 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Phibro Animal Health Corporation is NASDAQ-PAHC, and the stock is listed on NASDAQ.

Phibro Animal Health Corporation (NASDAQ-PAHC) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Phibro Animal Health Corporation is 37.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Phibro Animal Health Corporation is 51.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NASDAQ View more

AstraZeneca PLC ADR (AZN) AstraZeneca PLC ADR (AZN)
Sanofi ADR (SNY) Sanofi ADR (SNY)
Royalty Pharma Plc (RPRX) Royalty Pharma Plc (RPRX)
Viatris Inc (VTRS) Viatris Inc (VTRS)
Jazz Pharmaceuticals PLC (JAZZ) Jazz Pharmaceuticals PLC (JAZZ)
Axsome Therapeutics Inc (AXSM) Axsome Therapeutics Inc (AXSM)
Corcept Therapeutics Incorporated (CORT) Corcept Therapeutics Incorporated (CORT)
Crinetics Pharmaceuticals Inc (CRNX) Crinetics Pharmaceuticals Inc (CRNX)
Liquidia Technologies Inc (LQDA) Liquidia Technologies Inc (LQDA)
Belite Bio Inc ADR (BLTE) Belite Bio Inc ADR (BLTE)
Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Incorporated (LGND)
Definium Therapeutics Inc (DFTX) Definium Therapeutics Inc (DFTX)
Amneal Pharmaceuticals Inc Class A (AMRX) Amneal Pharmaceuticals Inc Class A (AMRX)
Indivior PLC (INDV) Indivior PLC (INDV)
Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX)
Enliven Therapeutics Inc (ELVN) Enliven Therapeutics Inc (ELVN)
Alumis Inc (ALMS) Alumis Inc (ALMS)
Structure Therapeutics Inc ADR (GPCR) Structure Therapeutics Inc ADR (GPCR)
MBX Biosciences Inc (MBX) MBX Biosciences Inc (MBX)
Supernus Pharmaceuticals Inc (SUPN) Supernus Pharmaceuticals Inc (SUPN)
ATAI Beckley Inc (ATAI) ATAI Beckley Inc (ATAI)
Regencell Bioscience Holdings Ltd (RGC) Regencell Bioscience Holdings Ltd (RGC)
Tarsus Pharmaceuticals Inc (TARS) Tarsus Pharmaceuticals Inc (TARS)
Trevi Therapeutics Inc (TRVI) Trevi Therapeutics Inc (TRVI)